General Principles of Cmab Interruption and Reintroduction

When the grade 3 or worse skin toxicities were observed at the day of Cmab administration, physician omitted Cmab at least one week, and restarted it after the toxicity recovered to Grade 2 or less. In addition, if it is judged that trend of exacerbation was apparent, physician could skip Cmab even in the case of grade 2 skin toxicity, and restarted it as soon as the toxicity recovered to acceptable Grade 2 or less. For patients who experienced Cmab interruption, additional medications (e.g., oral antihistamine and antibiotics, topical antibiotics and a higher-potency topical steroid) were considered at a physician's and dermatologist's discretion. Additionally, when Cmab interruption continued even though the additional medication was given, dose reduction of Cmab could be applied (e.g. dose level 0: 250mg/m², dose level−1: 200mg/m², dose level−2: 150mg/m²). In case that further dose reduction is required after doses of cetuximab reduced by 2 levels, the discontinuation of Cmab was considered.